ClearPoint Neuro, Inc.
Financials
Valuation Metrics
ClearPoint Neuro, Inc.'s Market Cap is $412M. At end of 2025 it was $387M. Ranked #2865 of 3,121 in US market (top 92%), #1272 of 1,463 on NASDAQ (top 87%), #177 of 205 in Health Care Equipment & Services (top 86%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $412M | US#2,865/3,121 Sec#177/205 |
| Revenue | $42M | US#2,786/3,121 Sec#195/205 |
| Net Income | $-35M | US—/3,121 Sec—/205 |
| Total Assets | $87M | US#3,069/3,121 Sec#203/205 |
| Net Assets | $11M | US#2,911/3,121 Sec#192/205 |
| Employees | 172 | US#2,517/3,121 Sec#173/205 |
| Value | ||
| P/B | 38.24x | US#2,873/3,121 Sec#188/205 |
| P/S | 9.75x | US#2,681/3,121 Sec#183/205 |
| FCF Yield | -7.59% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROA | -39.85% | US#2,946/3,121 Sec#194/205 |
| Op. Margin | -73.42% | US#2,710/3,121 Sec#190/205 |
| Revenue Growth | 25.86% | US#507/3,121 Sec#27/205 |
| Financial Health | ||
| Debt Ratio | 704.95% | US#2,535/3,121 Sec#186/205 |
| Total Debt | $64M | US#2,561/3,121 Sec#150/205 |
| FCF | $-31M | US#2,476/3,121 Sec#171/205 |
| Cash | $29M | US#2,769/3,121 Sec#181/205 |
| Current Ratio | 4.73x | US#510/3,121 Sec#42/205 |
| Performance | ||
| 1Y Return | 28.89% | US#940/3,121 Sec#74/205 |
| 1M Return | -9.49% | US#2,391/3,121 Sec#165/205 |
| From 52W High | -54.35% | US#2,826/3,121 Sec#184/205 |
| 1Y MDD | -70.74% | US#2,970/3,121 Sec#187/205 |
| Trading | ||
| Volume | 471,827 shares | US#2,062/3,121 Sec#146/205 |
| Trading Value | $6M | US#2,565/3,121 Sec#167/205 |
| Per Share | ||
| EPS | $-1.15 | US—/3,121 Sec—/205 |
| BPS | $0.36 | US#2,774/3,121 Sec#189/205 |
Company Info
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.